AlphaRose Therapeutics Acquires Alpha Anomeric SA
April 29, 2025
AlphaRose Therapeutics has acquired Alpha Anomeric SA, a Paris-based developer of the abcDNA oligonucleotide chemistry platform. The acquisition brings a proprietary antisense oligonucleotide chemistry into AlphaRose's portfolio and establishes a European presence to support global development of its neurogenetic and rare-disease programs. Terms were not disclosed.
- Buyers
- AlphaRose Therapeutics
- Targets
- Alpha Anomeric SA
- Industry
- Biotechnology
- Location
- France
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics
January 9, 2026
Biotechnology
Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.
-
Altos Labs Acquires Dorian Therapeutics
May 23, 2025
Biotechnology
Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.
-
Oncodesign Services Acquires ZoBio; Eurazeo's Nov Santé Invests in Oncodesign
January 23, 2023
Biotechnology
Oncodesign Services, majority-held by ERES IV SLP (Edmond de Rothschild Private Equity), has acquired Dutch fragment-based drug discovery specialist ZoBio to strengthen its upstream Drug Discovery capabilities. Concurrently, Nov Santé Actions Non Cotées (managed by Eurazeo) has invested in Oncodesign Services to support external growth and the group's international expansion.
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Biotage AB Acquires ATDBio
October 20, 2021
Biotechnology
Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.
-
Eurogentec S.A. Acquires AnaSpec Inc.
October 26, 2009
Biotechnology
Eurogentec S.A. has signed a definitive agreement to acquire AnaSpec Inc., a Fremont, California-based proteomics company that provides peptides, labeled peptides, fluorescent dyes and assay kits for research and diagnostics. The acquisition expands Eurogentec's genomics and proteomics capabilities and strengthens its geographic presence in the United States, while AnaSpec's founders and senior management will remain with the business.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.